King Pharmaceuticals, Inc.
Table of Contents

 
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 28, 2007 (February 28, 2007)
King Pharmaceuticals, Inc.
 
(Exact name of registrant as specified in charter)
         
Tennessee   001-15875   54-1684963
 
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification No.)
     
501 Fifth Street, Bristol, Tennessee   37620
 
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (423) 989-8000
N/A
 
(Former name or former address, if changed since last report)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
Ex-99.1 February 28, 2007 Press Release

Table of Contents

Item 2.02   Results of Operations and Financial Condition.
          On February 28, 2007, King Pharmaceuticals, Inc. issued a press release announcing its results of operations for the year and quarter ended December 31, 2006. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01   Financial Statements and Exhibits.
          (d)       Exhibits
  99.1   Press release of King Pharmaceuticals, Inc. dated February 28, 2007.

 

Table of Contents

SIGNATURES
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
             
Date: February 28, 2007   KING PHARMACEUTICALS, INC.    
 
            
 
  By:   /s/ Joseph Squicciarino
 
Joseph Squicciarino
Chief Financial Officer 		   

 

Table of Contents

EXHIBIT INDEX
     
Exhibit No.   Description
 
    
99.1
  Press release of King Pharmaceuticals, Inc. dated February 28, 2007.